Sars-CoV2
Conditions
Brief summary
Prospective assay for SARS-CoV-2 antibody detection indirectly by immunofluorescence: SARS-CoV2 IIF method
Detailed description
Sample preparation, serum separation by centrifugation * 100 µl of serum for standard SARS-CoV2 ELISA is used according to the instructions for use. * 100 µl of serum indirect immunofluorescent (IIF) method is used, the samples thus prepared analysis is performed under an automated microscope
Interventions
DIAGNOSTIC_TESTImmunfluorescence
Serum indirect immunofluorescent (IIF) method is used, analysis is performed under an automated microscope.
Sponsors
Bilogical Research Centre, Szeged
Szeged University
Study design
Observational model
CASE_CONTROL
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Person over 18 years of age * Signing a package leaflet and a informal consent * In the case of a positive group, confirmed by SARS-CoV2 qPCR Patient with COVID-19 or recovered individual. * In case of negative group by SARS-CoV2 qPCR test 2 negative in COVID-19 suffering individual
Exclusion criteria
* Refuses to sign the consent form
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Sensitivity of the method by SARS-CoV2 ELISA compared | 8 months | Sensitivity of the method by SARS-CoV2 ELISA compared |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Detectability of the antibodies IgA type against SARS-CoV2 virus | 8 months | Detectability of the antibodies IgA type against SARS-CoV2 virus in the early stages of the disease. |
Countries
Hungary
Contacts
Primary ContactKatalin Burián, MD
Backup ContactDávid Pintér, Pharm. D.
Outcome results
None listed